Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Teresa Helsten, Sheryl K. Elkin, Elisa Arthur, et al.
Clinical Cancer Research (2015) Vol. 22, Iss. 1, pp. 259-267
Open Access | Times Cited: 688

Showing 1-25 of 688 citing articles:

Mechanisms of receptor tyrosine kinase activation in cancer
Zhenfang Du, Christine M. Lovly
Molecular Cancer (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 864
Advances and challenges in targeting FGFR signalling in cancer
Irina S. Babina, Nicholas C. Turner
Nature reviews. Cancer (2017) Vol. 17, Iss. 5, pp. 318-332
Closed Access | Times Cited: 686
Inferring expressed genes by whole-genome sequencing of plasma DNA
Peter Ulz, Gerhard Thallinger, Martina Auer, et al.
Nature Genetics (2016) Vol. 48, Iss. 10, pp. 1273-1278
Open Access | Times Cited: 368
Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets
Eugene J. Pietzak, Aditya Bagrodia, K. Eugene, et al.
European Urology (2017) Vol. 72, Iss. 6, pp. 952-959
Open Access | Times Cited: 326
From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
Christopher Nevala-Plagemann, Manuel Hidalgo, Ignacio Garrido‐Laguna
Nature Reviews Clinical Oncology (2019) Vol. 17, Iss. 2, pp. 108-123
Closed Access | Times Cited: 311
Fibroblast growth factor receptors as treatment targets in clinical oncology
Masaru Katoh
Nature Reviews Clinical Oncology (2018) Vol. 16, Iss. 2, pp. 105-122
Closed Access | Times Cited: 301
Molecular targeted therapies: Ready for “prime time” in biliary tract cancer
Ángela Lamarca, Jorge Barriuso, Mairéad G. McNamara, et al.
Journal of Hepatology (2020) Vol. 73, Iss. 1, pp. 170-185
Open Access | Times Cited: 300
Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance
Alison M. Schram, Matthew T. Chang, Philip Jonsson, et al.
Nature Reviews Clinical Oncology (2017) Vol. 14, Iss. 12, pp. 735-748
Open Access | Times Cited: 276
Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application
Young Kwang Chae, Keerthi Ranganath, Peter S. Hammerman, et al.
Oncotarget (2016) Vol. 8, Iss. 9, pp. 16052-16074
Open Access | Times Cited: 269
Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance
Melanie A. Krook, Julie W. Reeser, Gabrielle Ernst, et al.
British Journal of Cancer (2020) Vol. 124, Iss. 5, pp. 880-892
Open Access | Times Cited: 256
Current best practice for bladder cancer: a narrative review of diagnostics and treatments
Éva Compérat, Mahul B. Amin, Richard Cathomas, et al.
The Lancet (2022) Vol. 400, Iss. 10364, pp. 1712-1721
Open Access | Times Cited: 231
Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer
Juan Miguel Cejalvo, Eduardo Martínez de Dueñas, Patricia Galván, et al.
Cancer Research (2017) Vol. 77, Iss. 9, pp. 2213-2221
Open Access | Times Cited: 220
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm
Yoshiaki Nakamura, Akihito Kawazoe, Florian Lordick, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 8, pp. 473-487
Closed Access | Times Cited: 216
Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors HarboringFGF/FGFRAberrations: A Phase I Dose-Expansion Study
Funda Meric‐Bernstam, Rastislav Bahleda, Cinta Hierro, et al.
Cancer Discovery (2021) Vol. 12, Iss. 2, pp. 402-415
Open Access | Times Cited: 201
FGFR a promising druggable target in cancer: Molecular biology and new drugs
Rut Porta, Roberto Borea, Andreia Coelho, et al.
Critical Reviews in Oncology/Hematology (2017) Vol. 113, pp. 256-267
Open Access | Times Cited: 189
Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
Aradhana Rani, Justin Stebbing, Georgios Giamas, et al.
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 189
Therapeutics Targeting FGF Signaling Network in Human Diseases
Masaru Katoh
Trends in Pharmacological Sciences (2016) Vol. 37, Iss. 12, pp. 1081-1096
Closed Access | Times Cited: 187
Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach
Marco Presta, Paola Chiodelli, Arianna Giacomini, et al.
Pharmacology & Therapeutics (2017) Vol. 179, pp. 171-187
Closed Access | Times Cited: 183
N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer
Yutian Zou, Shaoquan Zheng, Xinhua Xie, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 165
<p>Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies</p>
Fiona H. Tan, Tracy L. Putoczki, Stanley S. Stylli, et al.
OncoTargets and Therapy (2019) Vol. Volume 12, pp. 635-645
Open Access | Times Cited: 164
Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors
Hiroshi Sootome, Hidenori Fujita, Kenjiro Ito, et al.
Cancer Research (2020) Vol. 80, Iss. 22, pp. 4986-4997
Open Access | Times Cited: 156
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
Martin Schüler, Byoung Chul Cho, Cyrus Sayehli, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 10, pp. 1454-1466
Closed Access | Times Cited: 153
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies
Vivek Subbiah, Nicholas Iannotti, Martin Gutierrez, et al.
Annals of Oncology (2022) Vol. 33, Iss. 5, pp. 522-533
Open Access | Times Cited: 150
Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
Eric Santoni‐Rugiu, Linea Cecilie Melchior, Edyta Maria Urbanska, et al.
Cancers (2019) Vol. 11, Iss. 7, pp. 923-923
Open Access | Times Cited: 149
INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models
Phillip C.C. Liu, Holly K. Koblish, Liangxing Wu, et al.
PLoS ONE (2020) Vol. 15, Iss. 4, pp. e0231877-e0231877
Open Access | Times Cited: 141
Page 1 - Next Page

Scroll to top